Vor Biopharma director granted 42,658 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vor Biopharma director David Zaccardelli received a new stock option grant. The award covers 42,658 options to buy Vor Biopharma common stock at an exercise price of $20.10 per share and expires on July 6, 2036. These options will vest in 36 equal monthly installments beginning on August 7, 2026, contingent on his continued service with the company.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 42,658 | $0.00 | $0.00 |
Footnotes (1)
- F1. The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on August 7, 2026, in each case subject to the Reporting Person's continued service as of each such date.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
exercise price financial
expiration date financial
vesting financial
underlying security financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Vor Biopharma (VOR) disclose about David Zaccardelli in this Form 4?
How many Vor Biopharma (VOR) stock options were granted to David Zaccardelli?
What is the exercise price of David Zaccardelli’s Vor Biopharma (VOR) stock options?
When do David Zaccardelli’s Vor Biopharma (VOR) stock options start vesting?
When do David Zaccardelli’s Vor Biopharma (VOR) stock options expire?
Are David Zaccardelli’s Vor Biopharma (VOR) options immediately exercisable?
AI-generated analysis. How Rhea-AI works. Not financial advice.